Takeda Pharmaceutical Co., Ltd. (TAK)
17.86
0.00 (0.00%)
USD |
NYSE |
Oct 02, 16:00
17.86
0.00 (0.00%)
Pre-Market: 20:00
Takeda Pharmaceutical Enterprise Value : 84.01B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 84.01B |
| October 01, 2026 | 84.01B |
| September 30, 2026 | 85.06B |
| September 29, 2026 | 86.07B |
| September 28, 2026 | 87.30B |
| September 25, 2026 | 87.17B |
| September 24, 2026 | 86.32B |
| September 23, 2026 | 87.02B |
| September 22, 2026 | 87.46B |
| September 21, 2026 | 87.27B |
| September 18, 2026 | 87.33B |
| September 17, 2026 | 87.77B |
| September 16, 2026 | 86.48B |
| September 15, 2026 | 86.67B |
| September 14, 2026 | 86.35B |
| September 11, 2026 | 85.28B |
| September 10, 2026 | 84.80B |
| September 09, 2026 | 85.12B |
| September 08, 2026 | 85.47B |
| September 04, 2026 | 85.88B |
| September 03, 2026 | 86.70B |
| September 02, 2026 | 85.81B |
| September 01, 2026 | 85.18B |
| August 31, 2026 | 84.39B |
| August 28, 2026 | 84.55B |
| Date | Value |
|---|---|
| August 27, 2026 | 84.55B |
| August 26, 2026 | 85.18B |
| August 25, 2026 | 85.56B |
| August 24, 2026 | 85.21B |
| August 21, 2026 | 85.02B |
| August 20, 2026 | 84.87B |
| August 19, 2026 | 85.53B |
| August 18, 2026 | 84.61B |
| August 17, 2026 | 82.50B |
| August 14, 2026 | 83.29B |
| August 13, 2026 | 82.53B |
| August 12, 2026 | 82.59B |
| August 11, 2026 | 82.81B |
| August 10, 2026 | 83.03B |
| August 07, 2026 | 82.72B |
| August 06, 2026 | 81.36B |
| August 05, 2026 | 80.41B |
| August 04, 2026 | 79.90B |
| August 03, 2026 | 80.76B |
| July 31, 2026 | 81.58B |
| July 30, 2026 | 82.09B |
| July 29, 2026 | 83.67B |
| July 28, 2026 | 82.94B |
| July 27, 2026 | 82.69B |
| July 24, 2026 | 82.05B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Sanofi | 106.16B |
| Daiichi Sankyo Co., Ltd. | 30.79B |
| Ono Pharmaceutical Co., Ltd. | 6.161B |
| Astellas Pharma, Inc. | 27.81B |
| Eisai Co., Ltd. | 8.332B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 710.72M |
| Revenue (Quarterly) | 7.655B |
| Total Expenses (Quarterly) | 6.945B |
| EPS Diluted (Quarterly) | 0.2213 |
| Gross Profit Margin (Quarterly) | 57.57% |
| Profit Margin (Quarterly) | 9.28% |
| Earnings Yield | -1.89% |
| Operating Earnings Yield | 8.04% |
| Normalized Earnings Yield | -1.004 |